应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01548 金斯瑞生物科技
耶稣受难节休市 03-28 16:08:03
14.500
+0.300
+2.11%
最高
14.900
最低
14.100
成交量
961.94万
今开
14.100
昨收
14.200
日振幅
5.63%
总市值
307.87亿
流通市值
307.87亿
总股本
21.23亿
成交额
1.41亿
换手率
0.45%
流通股本
21.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
金斯瑞生物科技(01548)根据限制性股份奖励计划发行44.79万股新股
智通财经 · 03-26 12:25
金斯瑞生物科技(01548)根据限制性股份奖励计划发行44.79万股新股
金斯瑞生物科技3月25日遭南向资金减持286.40万股
自选股智能写手 · 03-26 09:31
金斯瑞生物科技3月25日遭南向资金减持286.40万股
金斯瑞生物科技(01548)下跌5.03%,报14.74元/股
金融界 · 03-22
金斯瑞生物科技(01548)下跌5.03%,报14.74元/股
金斯瑞生物科技盘中异动 早盘股价大跌5.03%报14.741港元
自选股智能写手 · 03-22
金斯瑞生物科技盘中异动 早盘股价大跌5.03%报14.741港元
金斯瑞生物科技03月21日遭主力抛售1772万元 环比增加162.91%
自选股智能写手 · 03-21
金斯瑞生物科技03月21日遭主力抛售1772万元 环比增加162.91%
金斯瑞生物科技3月20日获南向资金加仓505.20万股
自选股智能写手 · 03-21
金斯瑞生物科技3月20日获南向资金加仓505.20万股
金斯瑞生物科技(01548.HK):传奇生物发布首份ESG报告
格隆汇资讯 · 03-19
金斯瑞生物科技(01548.HK):传奇生物发布首份ESG报告
港股异动 | 金斯瑞生物科技(01548)跌超7% CDMO短期需求及盈利能力或承压 中金下调公司盈测及目标价
智通财经网 · 03-19
港股异动 | 金斯瑞生物科技(01548)跌超7% CDMO短期需求及盈利能力或承压 中金下调公司盈测及目标价
港股异动 | 药明康德(02359)一度跌近10%领跌CRO概念股 去年营收破400亿 增长仍靠欧美市场
智通财经 · 03-19
港股异动 | 药明康德(02359)一度跌近10%领跌CRO概念股 去年营收破400亿 增长仍靠欧美市场
金斯瑞生物科技盘中异动 股价大跌5.01%
自选股智能写手 · 03-19
金斯瑞生物科技盘中异动 股价大跌5.01%
金斯瑞生物科技(01548)下跌5.02%,报15.9元/股
金融界 · 03-19
金斯瑞生物科技(01548)下跌5.02%,报15.9元/股
金斯瑞生物科技3月15日获南向资金加仓517.29万股
自选股智能写手 · 03-18
金斯瑞生物科技3月15日获南向资金加仓517.29万股
金斯瑞生物科技(01548.HK)附属传奇生物(LEGN.US)新药获美FDA积极意见
阿斯达克财经 · 03-18
金斯瑞生物科技(01548.HK)附属传奇生物(LEGN.US)新药获美FDA积极意见
智通港股早知道 | 工信部将研究制定汽车以旧换新、充换电基础设施建设等支持政策 央行:前两月社融增量8.06万亿
智通财经 · 03-18
智通港股早知道 | 工信部将研究制定汽车以旧换新、充换电基础设施建设等支持政策 央行:前两月社融增量8.06万亿
港股公告掘金 | 福耀玻璃2023年度归母利润约56.29亿元 同比增长18.37% 拟每股派息1.3元
智通财经 · 03-17
港股公告掘金 | 福耀玻璃2023年度归母利润约56.29亿元 同比增长18.37% 拟每股派息1.3元
金斯瑞生物科技(01548):CARVYKTI®获美国FDA肿瘤药物咨询委员会用于治疗复发或难治性多发性骨髓瘤患者早期治疗的推荐
智通财经 · 03-17
金斯瑞生物科技(01548):CARVYKTI®获美国FDA肿瘤药物咨询委员会用于治疗复发或难治性多发性骨髓瘤患者早期治疗的推荐
东吴证券:维持金斯瑞生物科技“买入”评级 FY24Q2单季毛利率创新高
新浪港股 · 03-15
东吴证券:维持金斯瑞生物科技“买入”评级 FY24Q2单季毛利率创新高
东吴证券:维持金斯瑞生物科技(01548)“买入”评级 FY24Q2单季毛利率创新高
智通财经网 · 03-15
东吴证券:维持金斯瑞生物科技(01548)“买入”评级 FY24Q2单季毛利率创新高
南向资金3月14日净卖出金斯瑞生物科技71.60万股 连续5日减持
自选股智能写手 · 03-15
南向资金3月14日净卖出金斯瑞生物科技71.60万股 连续5日减持
加载更多
公司概况
公司名称:
金斯瑞生物科技
所属市场:
SEHK
上市日期:
--
主营业务:
制造及销售生命科学研究产品及服务。产品及服务主要包括生命科学研究服务、临床前药物研发服务、生命科学研究目录产品及工业合成生物产品。
发行价格:
--
{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":14.5,"timestamp":1711613283014,"preClose":14.2,"halted":0,"volume":9619438,"delay":0,"floatShares":2123264624,"shares":2123264624,"eps":-0.35428977,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":0.3,"latestTime":"03-28 16:08:03","open":14.1,"high":14.9,"low":14.1,"amount":140761250,"amplitude":0.056338,"askPrice":14.52,"askSize":10000,"bidPrice":14.5,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.35457156946390406,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1451404800000,"adjPreClose":14.2,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.9778596788217595,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"2422635635","title":"金斯瑞生物科技(01548)根据限制性股份奖励计划发行44.79万股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422635635","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422635635?lang=zh_cn&edition=full","pubTime":"2024-03-26 12:25","pubTimestamp":1711427144,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金斯瑞生物科技(01548)发布公告,于2024年3月25日根据于2021年8月23日采纳的限制性股份奖励计划而发行及配发的44.79万股新股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092175.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422683926","title":"金斯瑞生物科技3月25日遭南向资金减持286.40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422683926","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422683926?lang=zh_cn&edition=full","pubTime":"2024-03-26 09:31","pubTimestamp":1711416675,"startTime":"0","endTime":"0","summary":"3月25日,南向资金减持金斯瑞生物科技286.40万股。截止当日收盘,港股通共持有金斯瑞生物科技57202.27万股,占流通股26.93%。港股通减持金额前五个股分别为中国海洋石油、汇丰控股、泡泡玛特、吉利汽车、中芯国际。金斯瑞生物科技近5个交易日下跌10.99%,港股通累计增持730.01万股;近20个交易日下跌3.12%,港股通累计增持1420.29万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260946198b6340e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260946198b6340e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421880115","title":"金斯瑞生物科技(01548)下跌5.03%,报14.74元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421880115","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421880115?lang=zh_cn&edition=full","pubTime":"2024-03-22 10:39","pubTimestamp":1711075194,"startTime":"0","endTime":"0","summary":"3月22日,金斯瑞生物科技(01548)盘中下跌5.03%,截至10:39,报14.74元/股,成交6872.21万元。金斯瑞生物科技股份有限公司是一家全球重要的生命科学研发与生产服务提供商,主要业务包括生命科学服务及产品、生物医药合同研发生产、工业合成产品和综合性全球细胞疗法。截至2022年12月31日,公司在全球拥有6213名员工,拥有超过210项授权专利与800多项专利申请,业务覆盖全球100多个国家和地区,为20余万客户提供服务与产品。截至2023年年报,金斯瑞生物科技营业总收入59.46亿元、净利润-6.76亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/22103939951536.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421588052","title":"金斯瑞生物科技盘中异动 早盘股价大跌5.03%报14.741港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421588052","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421588052?lang=zh_cn&edition=full","pubTime":"2024-03-22 10:39","pubTimestamp":1711075193,"startTime":"0","endTime":"0","summary":"2024年03月22日早盘10时39分,金斯瑞生物科技股票出现波动,股价急速下挫5.03%。截至发稿,该股报14.741港元/股,成交量459.062万股,换手率0.22%,振幅5.03%。资金方面,该股资金流入2280.97万港元,流出3494.14万港元。金斯瑞生物科技股票所在的生物技术行业中,整体跌幅为1.53%。金斯瑞生物科技公司简介:金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403221039547a4e622a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403221039547a4e622a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421606050","title":"金斯瑞生物科技03月21日遭主力抛售1772万元 环比增加162.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421606050","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421606050?lang=zh_cn&edition=full","pubTime":"2024-03-21 16:15","pubTimestamp":1711008915,"startTime":"0","endTime":"0","summary":"03月21日, 金斯瑞生物科技股价跌1.77%,报收15.52元,成交金额1.92亿元,换手率0.58%,振幅3.16%,量比0.62。金斯瑞生物科技今日主力资金净流出1772万元,上一交易日主力净流出674万元,今日环比增加162.91%。该股近5个交易日下跌6.70%,主力资金累计净流入584万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入4778万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403211615338b4ffd95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403211615338b4ffd95&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421031659","title":"金斯瑞生物科技3月20日获南向资金加仓505.20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421031659","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421031659?lang=zh_cn&edition=full","pubTime":"2024-03-21 09:31","pubTimestamp":1710984668,"startTime":"0","endTime":"0","summary":"3月20日, 南向资金增持金斯瑞生物科技505.20万股,连续4日增持。截止当日收盘,港股通共持有金斯瑞生物科技57074.06万股,占流通股26.87%。金斯瑞生物科技近5个交易日下跌8.56%,港股通累计增持1233.75万股;近20个交易日上涨9.12%,港股通累计增持1441.36万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321094216879f7297&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321094216879f7297&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420229690","title":"金斯瑞生物科技(01548.HK):传奇生物发布首份ESG报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2420229690","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2420229690?lang=zh_cn&edition=full","pubTime":"2024-03-19 20:46","pubTimestamp":1710852416,"startTime":"0","endTime":"0","summary":"格隆汇3月19日丨金斯瑞生物科技(01548.HK)公告,传奇生物科技股份有限公司(为公司非全资附属公司)于2024年3月19日发布了其首份环境、社会和管治(ESG)报告。ESG报告概述了传奇生物的ESG计划及符合永续会计准则委员会生物技术和制药行业标准的报告、传奇生物的ESG数据收集和披露路线图,以及其ESG道路的未来成长领域。ESG报告强调了传奇生物对患者、员工和社区的承诺,标志着传奇生物于ESG道路上迈出了基础性的一步,并期待在未来几年继续推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031920470287984534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031920470287984534&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420121891","title":"港股异动 | 金斯瑞生物科技(01548)跌超7% CDMO短期需求及盈利能力或承压 中金下调公司盈测及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2420121891","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2420121891?lang=zh_cn&edition=full","pubTime":"2024-03-19 15:23","pubTimestamp":1710833031,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,金斯瑞生物科技跌超7%,截至发稿,跌7.53%,报15.48港元,成交额3.32亿港元。消息面上,金斯瑞生物科技此前发布2023年度业绩,收益8.4亿美元,同比增加34.2%;股东应占亏损9547.7万美元,同比收窄57.91%。此外,中金近日指出,考虑到CDMO短期需求增长及盈利能力承压,下调2024年盈利预测至净亏损1.97亿美元,同时引入2025年盈利预测净亏损0.90亿美元。由于近期港股医药板块系统性调整,下调其目标价25.1%至23港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403191529058796edbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403191529058796edbd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420250945","title":"港股异动 | 药明康德(02359)一度跌近10%领跌CRO概念股 去年营收破400亿 增长仍靠欧美市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2420250945","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420250945?lang=zh_cn&edition=full","pubTime":"2024-03-19 09:50","pubTimestamp":1710813040,"startTime":"0","endTime":"0","summary":"消息面上,药明康德发布2023年度业绩,收入403.408亿元,同比增长2.5%;母公司持有者的应占溢利106.9亿元,同比增长21.3%;拟向全体股东每10股派发现金股息9.8336元(含税)。此外,据药明康德年报透露,公司预计2024年收入达到人民币383亿-405亿元,剔除特定商业化生产项目后将保持正增长。日前BIO在其官网更改原有的新闻内容,并宣布“药明康德已主动终止了其BIO会员资格”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1088204.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420257471","title":"金斯瑞生物科技盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420257471","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420257471?lang=zh_cn&edition=full","pubTime":"2024-03-19 09:36","pubTimestamp":1710812193,"startTime":"0","endTime":"0","summary":"2024年03月19日早盘09时36分,金斯瑞生物科技股票出现异动,股价快速下挫5.01%。金斯瑞生物科技股票所在的生物技术行业中,整体跌幅为0.46%。其相关个股中,圣诺医药-B、科伦博泰生物-B、科笛-B涨幅较大,振幅较大的相关个股有腾盛博药-B、金斯瑞生物科技、圣诺医药-B,振幅分别为8.57%、7.05%、6.13%。消息层面,截至09时36分,《金斯瑞生物科技公司点评:CARVYKTI用于早期治疗获ODAC推荐 加速前线扩展和产能提升》资讯为影响金斯瑞生物科技的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319093634791b4ffd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319093634791b4ffd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420625228","title":"金斯瑞生物科技(01548)下跌5.02%,报15.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420625228","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420625228?lang=zh_cn&edition=full","pubTime":"2024-03-19 09:35","pubTimestamp":1710812119,"startTime":"0","endTime":"0","summary":"3月19日,金斯瑞生物科技(01548)盘中下跌5.02%,截至09:35,报15.9元/股,成交2423.25万元。金斯瑞生物科技股份有限公司是一家全球重要的生命科学研发与生产服务提供商,主要业务包括生命科学服务及产品、生物医药合同研发生产、工业合成产品和综合性全球细胞疗法。截至2022年12月31日,公司在全球拥有6213名员工,拥有超过210项授权专利与800多项专利申请,业务覆盖全球100多个国家和地区,为20余万客户提供服务与产品。截至2023年年报,金斯瑞生物科技营业总收入59.46亿元、净利润-6.76亿元。3月18日,海通国际维持增持评级,目标价30.45港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/19093539897643.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420460021","title":"金斯瑞生物科技3月15日获南向资金加仓517.29万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420460021","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420460021?lang=zh_cn&edition=full","pubTime":"2024-03-18 09:31","pubTimestamp":1710725485,"startTime":"0","endTime":"0","summary":"3月15日, 南向资金增持金斯瑞生物科技517.29万股。截止当日收盘,港股通共持有金斯瑞生物科技56285.99万股,占流通股26.50%。金斯瑞生物科技近5个交易日上涨19.61%,港股通累计减持342.24万股;近20个交易日上涨23.03%,港股通累计增持667.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403180944308b40e064&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403180944308b40e064&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420461994","title":"金斯瑞生物科技(01548.HK)附属传奇生物(LEGN.US)新药获美FDA积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2420461994","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420461994?lang=zh_cn&edition=full","pubTime":"2024-03-18 08:45","pubTimestamp":1710722700,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(01548.HK) 公布,非全资附属传奇生物科技(LEGN.US) 已向美国证券交易委员会提交6-K表格,宣布美国食品药品管理局(FDA)肿瘤药物咨询委员会已推荐CARVYKTI(西达基奥仑赛,cilta-cel)用于既往接受过至少1线治疗(包括蛋白酶体抑制剂和免疫调节剂)的复发性和来那度胺难治性多发性骨髓瘤成人患者的治疗。(ek/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-15 16:25。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190702162421146_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190702162421146_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1334019/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2420465380","title":"智通港股早知道 | 工信部将研究制定汽车以旧换新、充换电基础设施建设等支持政策 央行:前两月社融增量8.06万亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2420465380","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420465380?lang=zh_cn&edition=full","pubTime":"2024-03-18 07:38","pubTimestamp":1710718696,"startTime":"0","endTime":"0","summary":"同时结合2024消费促进年工作安排,组织开展全国汽车换新消费季活动,调动各方力量参与,扩大政策的影响力。央行:前两月新增信贷6.37万亿 社融增量8.06万亿 M2增长8.7%2月末,广义货币余额299.56万亿元,同比增长8.7%。前两个月净投放现金7566亿元。前两个月人民币贷款增加6.37万亿元。初步统计,2024年前两个月社会融资规模增量累计为8.06万亿元,比上年同期少1.1万亿元。CDMO/CMO业务收入人民币1.41亿元,同比增长94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087516.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420008482","title":"港股公告掘金 | 福耀玻璃2023年度归母利润约56.29亿元 同比增长18.37% 拟每股派息1.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420008482","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420008482?lang=zh_cn&edition=full","pubTime":"2024-03-17 20:28","pubTimestamp":1710678532,"startTime":"0","endTime":"0","summary":"重大事项:雅迪控股(01585)附属拟3.52亿元收购无锡凌博电子技术的全部股权金斯瑞生物科技(01548):CARVYKTI获美国FDA肿瘤药物咨询委员会用于治疗复发或难治性多发性骨髓瘤患者早期治疗的推荐基石药业-B(02616)宣布舒格利单抗第五项适应症在中国获批,用于胃癌一线治疗经营业绩:中石化炼化工程(02386)发布2023年度业绩 股东应占利润23.35亿元 同比增加2.2% 拟派发末","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087499.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420489356","title":"金斯瑞生物科技(01548):CARVYKTI®获美国FDA肿瘤药物咨询委员会用于治疗复发或难治性多发性骨髓瘤患者早期治疗的推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2420489356","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420489356?lang=zh_cn&edition=full","pubTime":"2024-03-17 19:06","pubTimestamp":1710673594,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金斯瑞生物科技 发布公告,当地时间2024年3月15日,传奇生物在美国新泽西州萨默塞特宣布,美国食品药品监督管理局肿瘤药物咨询委员会建议CARVYKTI用于治疗复发或难治性多发性骨髓瘤成人患者,这些患者既往至少接受过一线治疗((包括一种蛋白酶体抑制剂和一种免疫调节剂)且对来那度胺耐药。该委员会根据其评估结果提供非约束性建议;由FDA作出最终药物是否批准的决定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087483.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419699387","title":"东吴证券:维持金斯瑞生物科技“买入”评级 FY24Q2单季毛利率创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2419699387","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2419699387?lang=zh_cn&edition=full","pubTime":"2024-03-15 10:19","pubTimestamp":1710469190,"startTime":"0","endTime":"0","summary":"东吴证券发布研究报告称,维持金斯瑞生物科技“买入”评级,业绩略超预期,上调2024-2025年归母净利润预测,分别由-1.14/-0.18亿美元上调至-0.62/0.33亿美元,预测2026年归母净利润为1.63亿美元。由于CARVYKTI处于商业化早期的快速放量阶段和公司处于由亏转盈的关键节点,公司成长性强。2023年实现营业收入8.42亿美元,净利润为-2.30亿美元,归母净利润为-0.95亿美元,上年度同期归母净利润为-2.27亿美元,亏损大幅收窄,业绩略超预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/tob/2024-03-15/doc-inankiex4740770.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2024-03-15/doc-inankiex4740770.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419496739","title":"东吴证券:维持金斯瑞生物科技(01548)“买入”评级 FY24Q2单季毛利率创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2419496739","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2419496739?lang=zh_cn&edition=full","pubTime":"2024-03-15 09:36","pubTimestamp":1710466594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,东吴证券发布研究报告称,维持金斯瑞生物科技“买入”评级,业绩略超预期,上调2024-2025年归母净利润预测,分别由-1.14/-0.18亿美元上调至-0.62/0.33亿美元,预测2026年归母净利润为1.63亿美元。东吴证券主要观点如下:细胞疗法业务亮点颇多,拉动公司业绩快速增长:公司的控股子公司传奇生物开发的CARVYKTI自2022年第二季度开始商业化销售以来,销售额快速增长,CARVYKTI在2023年销售额为5.0亿美元,同比增长273%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1086796.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419627349","title":"南向资金3月14日净卖出金斯瑞生物科技71.60万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2419627349","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419627349?lang=zh_cn&edition=full","pubTime":"2024-03-15 09:31","pubTimestamp":1710466267,"startTime":"0","endTime":"0","summary":"3月14日,南向资金减持金斯瑞生物科技71.60万股连续5日减持。截止当日收盘,港股通共持有金斯瑞生物科技55768.71万股,占流通股26.25%。港股通减持金额前五个股分别为中国海洋石油、李宁、中国移动、建设银行、安踏体育。金斯瑞生物科技近5个交易日上涨16.27%,港股通累计减持892.93万股;近20个交易日上涨25.90%,港股通累计增持256.93万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403150944118b3521b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403150944118b3521b9&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0657},{"period":"1month","weight":-0.1027},{"period":"3month","weight":-0.2699},{"period":"6month","weight":-0.2978},{"period":"1year","weight":-0.2102},{"period":"ytd","weight":-0.2699}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"制造及销售生命科学研究产品及服务。产品及服务主要包括生命科学研究服务、临床前药物研发服务、生命科学研究目录产品及工业合成生物产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.012915},{"month":2,"riseRate":0.555556,"avgChangeRate":0.078892},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.061679},{"month":4,"riseRate":0.625,"avgChangeRate":0.087187},{"month":5,"riseRate":0.5,"avgChangeRate":0.081056},{"month":6,"riseRate":0.625,"avgChangeRate":0.0574},{"month":7,"riseRate":0.5,"avgChangeRate":0.012771},{"month":8,"riseRate":0.375,"avgChangeRate":0.132663},{"month":9,"riseRate":0.375,"avgChangeRate":-0.108852},{"month":10,"riseRate":0.75,"avgChangeRate":0.142825},{"month":11,"riseRate":0.75,"avgChangeRate":0.077381},{"month":12,"riseRate":0.375,"avgChangeRate":0.084334}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}